---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007204"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:29:34.103929+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Shuttle Pharma prelim FY2025 net loss widens to ~$11-12M; G&A up 3.6x on investor ads

## Summary
- Preliminary FY2025 net loss expected between $10.9M and $12.1M vs $9.1M in FY2024; revenue remains zero.
- G&A expense surged to $5.2-5.8M from $1.4M, driven by $3.6M in investor relations advertising costs.
- Working capital turns negative to deficit of $0.7-0.8M from positive $0.7M; cash used for Molecule.ai acquisition and trial wind-down.
- Intangible assets of $9.8M from Molecule.ai acquisition; contingent consideration of $2.0M and consideration payable of $4.4M.
- All convertible notes converted to stock; company needs additional financing to continue as going concern.

## SEC filing metadata
- accession: 0001493152-26-007204
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315226007204/0001493152-26-007204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315226007204/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007204
- JSON: https://secwatch.observer/filing/0001493152-26-007204.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.